Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Other financing activities (2016 - 2025)

Neuroone Medical Technologies' Other financing activities history spans 6 years, with the latest figure at $22920.0 for Q4 2025.

  • For Q4 2025, Other financing activities rose 7.58% year-over-year to $22920.0; the TTM value through Dec 2025 reached -$121855.0, down 3478.29%, while the annual FY2024 figure was $20000.0, 91.48% down from the prior year.
  • Other financing activities reached $22920.0 in Q4 2025 per NMTC's latest filing, up from $21305.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $183359.0 in Q1 2023 to a low of -$216599.0 in Q3 2024.
  • Average Other financing activities over 4 years is $34962.6, with a median of $37698.0 recorded in 2023.
  • Peak YoY movement for Other financing activities: soared 139.92% in 2023, then plummeted 43.49% in 2024.
  • A 4-year view of Other financing activities shows it stood at $15713.0 in 2022, then skyrocketed by 139.92% to $37698.0 in 2023, then tumbled by 43.49% to $21305.0 in 2024, then rose by 7.58% to $22920.0 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Other financing activities are $22920.0 (Q4 2025), $21305.0 (Q4 2024), and -$216599.0 (Q3 2024).